JP2024524895A - 抗csp抗体 - Google Patents
抗csp抗体 Download PDFInfo
- Publication number
- JP2024524895A JP2024524895A JP2023576368A JP2023576368A JP2024524895A JP 2024524895 A JP2024524895 A JP 2024524895A JP 2023576368 A JP2023576368 A JP 2023576368A JP 2023576368 A JP2023576368 A JP 2023576368A JP 2024524895 A JP2024524895 A JP 2024524895A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211820P | 2021-06-17 | 2021-06-17 | |
| US63/211,820 | 2021-06-17 | ||
| PCT/US2022/033877 WO2022266383A1 (en) | 2021-06-17 | 2022-06-16 | Anti-csp antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524895A true JP2024524895A (ja) | 2024-07-09 |
| JP2024524895A5 JP2024524895A5 (cg-RX-API-DMAC7.html) | 2025-06-23 |
Family
ID=84526612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576368A Pending JP2024524895A (ja) | 2021-06-17 | 2022-06-16 | 抗csp抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11655290B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355774A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524895A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240047964A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117940450A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022292722B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309422A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014984A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022266383A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322413A (en) * | 2023-02-03 | 2025-09-01 | Atreca Inc | Variants of anti-CSP antibody |
| WO2025194069A1 (en) * | 2024-03-15 | 2025-09-18 | Atreca, Inc. | Anti-csp antibody variants |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017015634A2 (en) * | 2015-07-22 | 2017-01-26 | Eureka Therapeutics, Inc. | Constructs targeting psa peptide/mhc complexes and uses thereof |
| US20180362628A1 (en) * | 2016-03-21 | 2018-12-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| WO2020172220A1 (en) * | 2019-02-19 | 2020-08-27 | Atreca, Inc. | Anti-csp antibody variants |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3954643B2 (ja) | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質 |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9221902B2 (en) * | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| SG10201900183VA (en) * | 2011-04-28 | 2019-05-30 | Univ Leland Stanford Junior | Identification of polynucleotides associated with a sample |
-
2022
- 2022-06-16 CN CN202280053427.0A patent/CN117940450A/zh active Pending
- 2022-06-16 KR KR1020247001320A patent/KR20240047964A/ko active Pending
- 2022-06-16 US US17/842,351 patent/US11655290B2/en active Active
- 2022-06-16 JP JP2023576368A patent/JP2024524895A/ja active Pending
- 2022-06-16 EP EP22825865.3A patent/EP4355774A4/en active Pending
- 2022-06-16 AU AU2022292722A patent/AU2022292722B2/en active Active
- 2022-06-16 WO PCT/US2022/033877 patent/WO2022266383A1/en not_active Ceased
- 2022-06-16 IL IL309422A patent/IL309422A/en unknown
- 2022-06-16 MX MX2023014984A patent/MX2023014984A/es unknown
-
2023
- 2023-01-26 US US18/101,933 patent/US12545723B2/en active Active
-
2025
- 2025-08-19 AU AU2025220692A patent/AU2025220692A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017015634A2 (en) * | 2015-07-22 | 2017-01-26 | Eureka Therapeutics, Inc. | Constructs targeting psa peptide/mhc complexes and uses thereof |
| US20180362628A1 (en) * | 2016-03-21 | 2018-12-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
| WO2020172220A1 (en) * | 2019-02-19 | 2020-08-27 | Atreca, Inc. | Anti-csp antibody variants |
Non-Patent Citations (6)
| Title |
|---|
| 6WFY, PDB_00006WFY: "Crystal straucture of Fab224 in complex with NPNA4 peptide from cirumsporozoite protein, [online]", RCSB PDB, vol. pp.1-16, [検索日2026年04月16日], JPN6026017196, 29 July 2020 (2020-07-29), ISSN: 0005849683 * |
| IMGT/3DSTRUCTURE-DB CARD FOR 6WFY: "Fab 224, anti-NPNA4, IG, FAB-GAMMA-1_LAMBDA, [online]", IMGT/3DSTRUCTURE-DB AND IMGT/2DSTRUCTURE-DB, vol. pp.1-2, [検索日2026年04月10日], JPN6026017197, 3 December 2020 (2020-12-03), ISSN: 0005849684 * |
| OYEN D. ET AL.: "Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stab", SCI ADV, vol. vol.4(10):eaau8529, JPN6026017199, 10 October 2018 (2018-10-10), pages 1 - 11, ISSN: 0005849685 * |
| OYEN D. ET AL.: "Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozo", PROC NATL ACAD SCI USA, vol. vol.114(48), JPN6026017192, 28 November 2017 (2017-11-28), pages 10438 - 10445, ISSN: 0005849686 * |
| PHOLCHAREE T. ET AL.: "Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite", J MOL BIOL, vol. vol.432(4), JPN6026017193, 14 February 2020 (2020-02-14), pages 1048 - 1063, ISSN: 0005849687 * |
| PHOLCHAREE, T. ET AL.: "Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. fa", NAT COMMUN, vol. vol.12:1063, JPN6026017198, 16 February 2021 (2021-02-16), pages 1 - 14, ISSN: 0005849682 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022292722A1 (en) | 2024-01-04 |
| KR20240047964A (ko) | 2024-04-12 |
| US11655290B2 (en) | 2023-05-23 |
| MX2023014984A (es) | 2024-03-12 |
| EP4355774A4 (en) | 2025-05-07 |
| WO2022266383A1 (en) | 2022-12-22 |
| US12545723B2 (en) | 2026-02-10 |
| AU2022292722B2 (en) | 2025-05-22 |
| AU2025220692A1 (en) | 2025-09-11 |
| CN117940450A (zh) | 2024-04-26 |
| NZ806561A (en) | 2025-06-27 |
| US20230167169A1 (en) | 2023-06-01 |
| IL309422A (en) | 2024-02-01 |
| EP4355774A1 (en) | 2024-04-24 |
| US20230002483A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI778994B (zh) | 用於移除造血幹細胞的抗體藥物結合物 | |
| TW201819413A (zh) | Cd47抗體、其抗原結合片段及其醫藥用途 | |
| WO2019091449A1 (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| JP7308747B2 (ja) | 抗インターフェロンガンマ抗体およびその使用法 | |
| JP7538131B2 (ja) | 抗cd79b抗体、その抗原結合フラグメントおよびそれらの医薬用途 | |
| TW200836763A (en) | Pegylated Aβ FAB | |
| WO2022184074A1 (zh) | 含抗tslp抗体的药物组合物 | |
| US20190389939A1 (en) | Antibody against hepatitis b surface antigen and use thereof | |
| US12545723B2 (en) | Anti-CSP antibodies | |
| JP2026016483A (ja) | 抗ヒトtlr7抗体 | |
| JPWO2018070390A1 (ja) | 抗robo4抗体と他剤を含む組成物 | |
| WO2025217497A1 (en) | Albumin binding proteins and methods of use | |
| JP2022507599A (ja) | 安定性が向上した抗c-met抗体又はその抗原結合断片 | |
| US20260092103A1 (en) | Monoclonal antibodies to arabinomannan (am), groel2, and lprg and methods of use | |
| JP7748389B2 (ja) | 抗cd47抗体およびその使用 | |
| US20220195023A1 (en) | Anti-csp antibody variants | |
| OA21630A (en) | Anti-CSP antibodies. | |
| WO2025194069A1 (en) | Anti-csp antibody variants | |
| WO2021190500A1 (zh) | SARS-CoV-2和SARS-CoV交叉中和抗体的制备及应用 | |
| KR20260036054A (ko) | 항-csp 항체 변이체 | |
| RU2817143C2 (ru) | Антитело против cd79b, его антигенсвязывающий фрагмент и его фармацевтическое применение | |
| JP2025535498A (ja) | Cd24に対する抗体およびその使用 | |
| WO2025171256A1 (en) | Compositions and methods for treating malaria | |
| HK40059424B (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250613 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260727 |